Balsm Alofoq Medical Company CJSC
Balsm Alofoq Medical Company CJSC operates in the healthcare facilities and services industry, providing biotechnology-based medical services and solutions.
Business. Balsm Alofoq Medical Company CJSC is a healthcare services and equipment firm primarily engaged in biotechnology activities. The company is headquartered in Saudi Arabia and is listed on the Tadawul stock exchange under the ticker symbol 9620.SE. Specific details regarding its operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Balsm Alofoq Medical Company CJSC is a healthcare services and equipment firm primarily engaged in biotechnology activities. The company is headquartered in Saudi Arabia and is listed on the Tadawul stock exchange under the ticker symbol 9620.SE. Specific details regarding its operating segments and geographic revenue mix are not disclosed.
Balsm Alofoq Medical Company CJSC has a basic and diluted share count of 2.5 million shares outstanding, indicating no immediate dilution pressure from share issuance. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against industry_config preferred metrics or cohort medians. This lack of data limits the ability to assess its operational efficiency and financial health relative to peers.
Segment and geographic exposure details are not disclosed in the available data, which prevents a detailed analysis of revenue concentration or geographic diversification. Without this information, it is not possible to evaluate the company's exposure to regional economic or regulatory risks.
Growth trajectory data is also not available, as the outlook for the current and next fiscal years, along with numeric deltas, is not provided. This absence of forward-looking guidance hinders the ability to assess the company's growth potential or strategic direction.
The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unassessed due to missing balance-sheet data. No dilution sources are identified in the available documents, and no recent events such as filings or transcripts are provided to inform on potential risk factors.
Recent events, including filings or transcripts, are not disclosed in the available data, which limits the ability to assess the company's recent strategic or operational developments.
- The company has no immediate dilution pressure, with basic and diluted shares outstanding being equal.
- Liquidity risk could not be assessed due to missing balance-sheet data and lack of going-concern language.
- Profitability and return metrics are not available, limiting comparison with industry benchmarks.
- No segment or geographic exposure data is disclosed, making it difficult to evaluate diversification.
- Growth trajectory and forward-looking guidance are not provided, hindering assessment of future performance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Balsm Alofoq Medical Company CJSC Market data — financials · 2026-05-27